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Introduction
Bivalirudin is a small (MW 2180 Daltons) synthetic peptide modelled after hirudin and consists of 20 amino acids, containing two binding domains that bind directly and reversibly to the catalytic site and to the anion-binding exosite of thrombin (1, 2) . Bivalirudin is approved for use as an anticoagulant in patients with unstable angina undergoing percutaneous coronary interventions (3, 4) and under investigation in patients with acute coronary syndromes (5-7), acute myocardial infarction (8) (9) (10) (11) , and in cardiac surgery patients with heparin induced thrombocytopenia (HIT). Bivalirudin has been successfully used as an alternative anticoagulant to treat patients with HIT (12, 13) .
Hirudins are proteins 65 amino acids in length and of non-human origin (medical leech). Anti-hirudin antibody formation in patients treated with recombinant hirudins has been demonstrated in several studies: in a prospective trial 87/198 (44%) HIT-patients treated with lepirudin in therapeutic dose developed anti-hirudin antibodies of the IgG class (14) . In another study 74% of HIT patients developed antihirudin antibodies of the IgG-, IgA, and/or IgM-class (15, 16) . The risk of immunisation per time exposed seems to be in a similar range if desirudin, an r-hirudin similar to lepirudin, is given in prophylactic dose (desirudin 15mg s.c. bid) (17) . Antibodies of patients treated with desirudin showed a 100% cross-reactivity to lepirudin and vice versa, and therefore must recognize structures common to both hirudins with similar immunogenicity (17) . Recently lepirudin has been linked to at least nine cases of severe anaphylaxis, four of them with fatal outcome (18) .
The amino-acid sequence hirudin and bivalirudin have in common binds to the exosite 1 of thrombin, as do other thrombin substrates. Clinically significant antibody formation in response to bivalirudin monotherapy seems to be low, but as For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From immunogenicity of lepirudin is high and lepirudin and bivalirudin share a sequence of 11 amino acids ( Figure 1 ) we sought to determine the extent of in vitro crossreactivity of anti-lepirudin antibodies with bivalirudin.
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Methods

Study objective
The objective was to assess whether anti-lepirudin antibodies in sera of lepirudin-treated patients recognize epitopes on bivalirudin.
Sera The study included sera from HIT patients treated with lepirudin who developed anti-lepirudin antibodies. Patients were treated with lepirudin in therapeutic (bolus followed by aPTT adjusted i.v. infusion; n=32) or prophylactic (aPTT adjusted i.v. infusion; n=11) doses. Mean treatment duration was 13.9 days.
All sera were stored in aliquots at -30°C, thawed and tested. For inhibitory experiments sera were preincubated with high concentrations of either lepirudin (100 µg/ml and 400 µg/ml) or bivalirudin (1 mg/ml). As control, albumin was added in different concentrations (50, 100, 500, 1000 µg/ml).
Cut off values were defined based on serum samples from 100 healthy blood donors. Assay results were deemed negative or positive (99% quantile of blood donor data). All samples and standards were tested in duplicate.
OD values of binding experiments and of inhibitory experiments were compared by the Wilcoxon rank sum test. Albumin did not cause inhibition at any concentration tested (mean OD at 50 µg/ml 1.654 ± 0.119; 100 µg/ml 1.663 ± 0.124; 500 µg/ml 1.676 ±0.136; 1000 µg/ml 1.502 ± 0.141; buffer instead of albumin 1.600 ± 0.193). Each concentration was tested with 22 sera. there was an enhancing effect, and in 5 no biological effect could be seen when aPTT and lepirudin dose changes were assessed.
Relevance of the antibodies in vivo
For
Discussion
As bivalirudin and lepirudin have a segment of their respective amino acid sequences in common, cross-reactivity of anti-hirudin antibodies to this structurally similar site of bivalirudin is a plausible concept. Indeed, using sera of 43 wellcharacterised patients with anti-lepirudin antibodies, we confirmed this assumption:
22 sera (51.2%) contained antibodies binding to epitopes on bivalirudin (figure 2b).
Binding specificity was demonstrated by inhibition of >70% by preincubation with free bivalirudin. As binding of antibodies to lepirudin was not inhibited by high concentrations of bivalirudin whereas binding to bivalirudin was inhibited by both high concentrations of lepirudin and high concentrations of bivalirudin, patient sera must contain polyspecific antibodies recognizing different epitopes on the lepirudin molecule, some of them shared with bivalirudin.
Generally lower antibody binding to bivalirudin as compared to lepirudin was probably caused by the fact that bivalirudin does not share all of the epitopes to which the polyspecific response to lepirudin is directed. Thus, not all anti-hirudin antibodies in a particular patient serum can actually bind bivalirudin. Steric inhibition occurring after binding of the small bivalirudin molecule to the microtiter plate and different coating characteristics may also decrease antibody binding. (19, 20) , but only very rarely in healthy volunteers (21) or in patients with acute coronary syndromes treated with hirudins (22, 23) . Recently it became obvious that in patients treated with lepirudin for periods of more than 5 days, e.g. for treatment of heparin-induced thrombocytopenia, development of anti-hirudin antibodies is relatively common. These antibodies can be biologically relevant. As we observed previously (14) , also in this study the most common effect of the anti-lepirudin Our experiments lead to three important implications: firstly, in patients who have developed anti-lepirudin-antibodies, subsequent treatment with bivalirudin should be monitored carefully, because pharmacokinetic alterations might occur by reduced renal filtration of the bivalirudin-antibody -complexes. As the shared structure of both molecules is the functional part, cross-reacting anti-hirudin antibodies should preferably bind to these epitopes, potentially exerting additional functional effects, although we did not see a major difference in the biological effects between antibodies recognizing lepirudin alone and antibodies recognizing lepirudin and bivalirudin. The second conclusion, on a more speculative note, is that bivalirudin, sharing epitopes with lepirudin, might lead to boosting of anti-hirudin antibody titres, or even formation of anti-bivalirudin antibodies independent of any lepirudin treatment. Thirdly, and most importantly, anaphylaxis occurring in patients reexposed to lepirudin, presumably due to anti-lepirudin antibodies, might also occur upon exposing such patients to bivalirudin and vice versa.
Anti-hirudin antibody formation has been demonstrated in animal experiments
It is quite possible that the epitope generating the cross-reacting antibody may be different from those responsible for the severe immune responses upon reexposure, given the multiple epitopes on lepirudin which trigger antibody formation and the relatively small homologous sequence between lepirudin and bivalirudin.
However, for safety reasons caution is warranted when bivalirudin is used in patients who have been treated with lepirudin or desirudin. 
